Clik here to view.
Debiopharm and Genome ＆ Company Reach Agreement for Potential First-In Class...
LAUSANNE, Switzerland & SUWON-SI GYEONGGI-DO, South Korea Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based, biopharmaceutical company aiming to establish tomorrow’s...
View ArticleClik here to view.
ImmuneOncia Announces Biomarker Results from Phase 1 Clinical Trial of CD47...
SEOUL, South Korea ImmuneOncia (CEO Heung Tae Kim) announced the results of its solid tumour Phase 1a clinical trial of IMC-002, an anti-CD47 mAb, presented at the American Society of Clinical...
View ArticleClik here to view.
NCC and PeptiDream Announce the First Dosing of 64Cu-PD-32766 in a patient...
KAWASAKI, Japan National Cancer Center and PeptiDream Inc.: Overview The National Cancer Center (President: Hitoshi Nakagama) Hospital East (Director: Toshihiko Doi) and PeptiDream Inc., a public...
View ArticleClik here to view.
Avistone Announces Results from Two Sponsored Clinical Research Programs at...
BEIJING Beijing Avistone Biotechnology Co., Ltd. (also referred to as Avistone Biotechnology or Avistone), an innovative biotechnology company focused on precision oncology therapeutics, announced...
View ArticleClik here to view.
Body Vision Medical Signs Exclusive Distribution Agreement with AMCO...
CAMPBELL, Calif. Body Vision Medical, a leader in AI-driven, intraoperative imaging, announced today it has signed an exclusive distribution agreement with AMCO Incorporated to expand access of its...
View ArticleClik here to view.
ボディ・ビジョン・メディカル、株式会社アムコとの専属販売契約を締結
カリフォルニア州キャンベル （ビジネスワイヤ） — AI駆動の術中イメージング医療機器のリーディング・カンパニーであるボディ・ビジョン・メディカルは、自社の最新技術LungVision®のリアルタイム術中CTイメージング・システムへのアクセスを日本へ拡大すべく、株式会社アムコとの専属販売契約を締結したことを発表しました。...
View ArticleClik here to view.
Shaperon and Dong-A ST Sign MOU for Nanobody-Based New Drug Development
CAMBRIDGE, Mass & RESEARCH TRIANGLE PARK, N.C. & SEOUL, South Korea Hudson Therapeutics announced that Shaperon (KOSDAQ 378800, CEO Seung-Yong Seong), an innovative biopharmaceutical company...
View ArticleClik here to view.
血液学/肿瘤学：AOP Health不断扩大的临床研究项目取得新成果
维也纳 (美国商业资讯)– AOP Orphan Pharmaceuticals GmbH (AOP Health)继续在血液学/肿瘤学领域开展成功的临床研究项目。该公司的两篇摘要获准在西班牙马德里举行的欧洲血液学协会(EHA)...
View ArticleClik here to view.
血液学/腫瘍学：AOPヘルスの拡大する臨床研究プログラムで新たな結果が判明
ウィーン （ビジネスワイヤ） — AOP Orphan Pharmaceuticals GmbH...
View ArticleClik here to view.
InnoCare Announces Clearance of Clinical Trial of TYK2 Inhibitor ICP-332 by...
BEIJING InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the U.S. Food and Drug...
View ArticleClik here to view.
Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development...
SHANGHAI & CAMBRIDGE, Mass. Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced today that following a distinguished career, Harald Reinhart, M.D., President, Head of Global Development,...
View ArticleClik here to view.
Lantern Pharma Receives Certificate of Patent from Japanese Patent Office...
DALLAS Lantern Pharma Inc., (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning...
View ArticleClik here to view.
Data of InnoCare’s Robust Pipelines Presented at the European Hematology...
BEIJING Data of InnoCare’s (HKEX: 09969; SSE: 688428) robust pipelines were presented at the European Hematology Association (EHA) 2024 Hybrid Congress. 1. Subcutaneous ICP-B02 (CM355), a Novel...
View ArticleClik here to view.
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive...
OSAKA, Japan & CAMBRIDGE, Mass. Takeda (TSE:4502/NYSE:TAK) today announced the signing of an option agreement with Ascentage Pharma to enter into an exclusive license agreement for...
View ArticleClik here to view.
LIDE Biotech Showcases Lab Ops Quality with Participation in VERIF.i®,...
SAN DIEGO Scientist.com, the pharmaceutical industry’s leading R&D marketplace, announced today that LIDE Biotech has successfully completed VERIF.i® on-site assessments at two of its...
View ArticleClik here to view.
InnoCare Announces the Acceptance of Biologics License Application for...
BEIJING InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that China National Medical...
View ArticleClik here to view.
PharmaEssentia Appoints Fred Paster as Head of Commercial
BURLINGTON, Mass. PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven...
View ArticleClik here to view.
Takeda Receives Approval from European Commission for FRUZAQLA in Previously...
OSAKA, Japan & CAMBRIDGE, Mass. Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved FRUZAQLA (fruquintinib) as a monotherapy indicated for the treatment of...
View ArticleClik here to view.
Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and...
PETACH TIKVA, Israel Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and...
View ArticleClik here to view.
PharmaEssentia Completes Patient Enrollment for Phase 2b EXCEED-ET Trial in...
BURLINGTON, Mass. PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven...
View Article